Cristina Vazquez Guillamet

Medicine & Life Sciences

1. Acinetobacter 33%
2. Anti-Bacterial Agents 80%
3. Antimicrobial Stewardship 49%
4. Artificial Respiration 46%
5. B7-H1 Antigen 27%
6. Bacteremia 26%
7. Bronchoalveolar Lavage 18%
8. Candidemia 24%
9. Cefepime 25%
10. Clinical Decision Rules 25%
11. Cohort Studies 31%
12. Confidence Intervals 21%
13. Coronavirus 25%
14. Critical Care 37%
15. Critical Illness 78%
16. Decision Making 28%
17. Epidemiology 24%
18. Gram-Negative Bacteria 51%
19. Gram-Positive Bacteria 22%
20. Healthcare-Associated Pneumonia 28%
21. Hospital Mortality 24%
22. Hospital Rapid Response Team 27%
23. Immunocompromised Host 20%
24. Infections 87%
25. Intensive Care Units 72%
26. Lung 65%
27. Lung Transplantation 29%
28. Meropenem 23%
29. Methicillin-Resistant Staphylococcus aureus 55%
30. Microbial Drug Resistance 31%
31. Mortality 59%
32. Multiple Drug Resistance 20%
33. Numbers Needed To Treat 21%
34. Odds Ratio 23%
35. Pandemics 18%
36. Pneumonia 34%
37. Pseudomonas 21%
38. Retrospective Studies 19%
39. Sepsis 89%
40. Septic Shock 100%
41. Skilled Nursing Facilities 24%
42. Smoke 16%
43. Soft Tissue Infections 23%
44. Tazobactam Drug Combination Piperacillin 22%
45. Terminal Care 22%
46. Therapeutics 26%
47. Thorax 28%
48. Transplant Recipients 54%
49. Vancomycin-Resistant Enterococci 17%
50. Ventilator-Associated Pneumonia 67%